Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian working group consensus update

Canadian Journal of Cardiology

Volumn 29, Issue 12, 2013, Pages 1553-1568

  Mancini, G B John ^a   Tashakkor, A Yashar ^a   Baker, Steven ^b   Bergeron, Jean ^c   Fitchett, David ^d   Frohlich, Jiri ^a   Genest, Jacques ^e   Gupta, Milan ^b   Hegele, Robert A ^f   Ng, Dominic S ^d   Pearson, Glen J ^g   Pope, Janet ^h  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e MCGILL UNIVERSITY   (Canada)

^f ROBARTS RESEARCH INSTITUTE   (Canada)

^g UNIVERSITY OF ALBERTA   (Canada)

^h WESTERN UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; AMLODIPINE; ANTIFUNGAL AGENT; APOLIPOPROTEIN B; ATORVASTATIN; BRAIN DERIVED NEUROTROPHIC FACTOR; C REACTIVE PROTEIN; CREATINE KINASE; CYCLOSPORIN; DANAZOL; DILTIAZEM; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MACROLIDE; MEVINOLIN; NEFAZODONE; PITAVASTATIN; PRAVASTATIN; PROTEINASE INHIBITOR; ROSUVASTATIN; SIMVASTATIN; UBIDECARENONE; VERAPAMIL; VITAMIN D;

ABDOMINAL CRAMP; ACUTE KIDNEY FAILURE; ALCOHOL ABUSE; ALCOHOL CONSUMPTION; AMINOTRANSFERASE BLOOD LEVEL; ARTHRITIS; ASIAN; BRAIN HEMORRHAGE; CALCIUM HOMEOSTASIS; CARDIOVASCULAR RISK; CATARACT; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; COGNITION; COGNITIVE DEFECT; CONSENSUS DEVELOPMENT; CONSTIPATION; CREATINE KINASE BLOOD LEVEL; DERMATOMYOSITIS; DIABETES MELLITUS; DIABETIC RETINOPATHY; DIARRHEA; DISEASE ACTIVITY; DISEASE PREDISPOSITION; DIZZINESS; DRUG BLOOD LEVEL; DRUG HYPERSENSITIVITY; DRUG RECHALLENGE; DRUG USE; DRUG WITHDRAWAL; DYSPEPSIA; ERECTILE DYSFUNCTION; EXERCISE; EXERCISE TOLERANCE; FAMILY HISTORY; FATIGUE; FOLLOW UP; GENETIC ASSOCIATION; GYNECOMASTIA; HEADACHE; HEART FAILURE; HEREDITY; HIGH RISK POPULATION; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOTHYROIDISM; IMMUNOSUPPRESSIVE TREATMENT; INSULIN RESISTANCE; INTERNATIONAL NORMALIZED RATIO; INTERSTITIAL LUNG DISEASE; LONG TERM CARE; META ANALYSIS (TOPIC); MUSCLE STRENGTH; MYALGIA; MYOPATHY; MYOSITIS; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE PHOSPHORYLATION; PHASE 2 CLINICAL TRIAL (TOPIC); PITYRIASIS LICHENOIDES; POLYMYOSITIS; POPULATION BASED CASE CONTROL STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHABDOMYOLYSIS; RHEUMATOID ARTHRITIS; SEX DIFFERENCE; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION;

ALGORITHMS; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EVIDENCE-BASED MEDICINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MUSCULAR DISEASES; PATIENT EDUCATION AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 84888237339     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2013.09.023     Document Type: Review

References (155)

1. Mancini G.B., Baker S., Bergeron J., et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference. Can J Cardiol 2011, 27:635-662.
2. Mansi I., Frei C.R., Pugh M.J., Makris U., Mortensen E.M. Statins and musculoskeletal conditions, arthropathies, and injuries. JAMA Intern Med 2013, 173:1318-1326.
3. Thompson P.D., Clarkson P., Karas R.H. Statin-associated myopathy. JAMA 2003, 289:1681-1690.
4. Mammen A.L., Gaudet D., Brisson D., et al. Increased frequency of DRB1*11:01 in anti-hydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Care Res (Hoboken) 2012, 64:1233-1237.
5. Armour R., Zhou L. Outcomes of statin myopathy after statin withdrawal. JClin Neuromuscul Dis 2013, 14:103-109.
6. Savage R.L., Star K., Hill R. Severe muscle symptoms with lipid-lowering agents may be confused with neurogenic claudication associated with spinal canal stenosis. Int J Risk Saf Med 2012, 24:215-219.
7. Hubal M.J., Reich K.A., Biase A.D., et al. Transcriptional deficits in oxidative phosphorylation with statin myopathy. Muscle Nerve 2011, 44:393-401.
8. Galtier F., Mura T., Raynaud de Mauverger E., et al. Effect of a high dose of simvastatin on muscle mitochondrial metabolism and calcium signalling in healthy volunteers. Toxicol Appl Pharmacol 2012, 263:281-286.
9. Sirvent P., Fabre O., Bordenave S., et al. Muscle mitochondrial metabolism and calcium signaling impairment in patients treated with statins. Toxicol Appl Pharmacol 2012, 259:263-268.
10. Larsen S., Stride N., Hey-Mogensen M., et al. Simvastatin effects on skeletal muscle: relation to decreased mitochondrial function and glucose intolerance. JAm Coll Cardiol 2013, 61:44-53.
11. Garrison S.R., Dormuth C.R., Morrow R.L., Carney G.A., Khan K.M. Nocturnal leg cramps and prescription use that precedes them: a sequence symmetry analysis. Arch Intern Med 2012, 172:120-126.
12. Wu J.S., Buettner C., Smithline H., Ngo L.H., Greenman R.L. Evaluation of skeletal muscle during calf exercise by 31-phosphorus magnetic resonance spectroscopy in patients on statin medications. Muscle Nerve 2011, 43:76-81.
13. Mattman A., O'Riley M., Waters P.J., et al. Diagnosis and management of patients with mitochondrial disease. BC Med J 2001, 53:177-182.
14. Hannah-Shmouni F., Al-Sarraf A., Frohlich J., Mezei M.M., Sirrs S., Mattman A. Safety of statin therapy in patients with mitochondrial diseases. JClin Lipidol 2013, 7:182.
15. Li M., Al-Sarraf A., Mattman A., Frohlich J. Use of once-weekly statin in combination with ezetimibe in a patient with mitochondrial disease. BMJ Case Rep 2012, 2012. pii: bcr1220115369.
16. Padala S., Thompson P.D. Statins as a possible cause of inflammatory and necrotizing myopathies. Atherosclerosis 2012, 222:15-21.
17. Werner J.L., Christopher-Stine L., Ghazarian S.R., et al. Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Rheum 2012, 64:4087-4093.
18. Liang C., Needham M. Necrotizing autoimmune myopathy. Curr Opin Rheumatol 2011, 23:612-619.
19. Mammen A.L., Pak K., Williams E.K., et al. Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects. Arthritis Care Res (Hoboken) 2012, 64:269-272.
20. Semple S.J. Statin therapy, myopathy and exercise-a case report. Lipids Health Dis 2012, 11:40.
21. Mikus C.R., Boyle L.J., Borengasser S.J., et al. Simvastatin impairs exercise training adaptations. JAm Coll Cardiol 2013, 62:709-714.
22. Parker B.A., Augeri A.L., Capizzi J.A., et al. Effect of statins on creatine kinase levels before and after a marathon run. Am J Cardiol 2012, 109:282-287.
23. Thompson P.D., Parker B.A., Clarkson P.M., et al. Arandomized clinical trial to assess the effect of statins on skeletal muscle function and performance: rationale and study design. Prev Cardiol 2010, 13:104-111.
24. Parker B.A., Capizzi J.A., Grimaldi A.S., et al. Effect of statins on skeletal muscle function. Circulation 2013, 127:96-103.
25. Marcum Z.A., Vande Griend J.P., Linnebur S.A. FDA drug safety communications: a narrative review and clinical considerations for older adults. Am J Geriatr Pharmacother 2012, 10:264-271.
26. Golomb B.A., Criqui M.H., White H., Dimsdale J.E. Conceptual foundations of the UCSD Statin Study: a randomized controlled trial assessing the impact of statins on cognition, behavior, and biochemistry. Arch Intern Med 2004, 164:153-162.
27. Muldoon M.F., Ryan C.M., Sereika S.M., Flory J.D., Manuck S.B. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am J Med 2004, 117:823-829.
28. Muldoon M.F., Barger S.D., Ryan C.M., et al. Effects of lovastatin on cognitive function and psychological well-being. Am J Med 2000, 108:538-546.
29. Rojas-Fernandez C.H., Cameron J.C. Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations. Ann Pharmacother 2012, 46:549-557.
30. Ott B, Daiello L, Springate B, et al. Do statin drugs impair cognition? A systematic review and meta-analysis. Alzheimers Dement 2013;9(Suppl):P666.
31. McGuinness B., O'Hare J., Craig D., Bullock R., Malouf R., Passmore P. Cochrane review on 'Statins for the treatment of dementia'. Int J Geriatr Psychiatry 2013, 28:119-126.
32. Pandey R.D., Gupta P.P., Jha D., Kumar S. Role of statins in Alzheimer's disease: a retrospective meta-analysis for commonly investigated clinical parameters in RCTs. Int J Neurosci 2013, 123:521-525.
33. Abdulrazzaq H.A., Sulaiman S.A. Neurological adverse drug reactions and statin therapy. Int J Pharm Pharm Sci 2012, 4:446-449.
34. Golomb B.A., Evans M.A., Dimsdale J.E., White H.L. Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial. Arch Intern Med 2012, 172:1180-1182.
35. Hoogwegt M.T., Theuns D.A., Kupper N., Jordaens L., Pedersen S.S. Relation of statin therapy to psychological functioning in patients with an implantable cardioverter defibrillator. Am J Cardiol 2013, 111:1169-1174.
36. Mansi I., Frei C.R., Pugh M.J., Mortensen E.M. Psychologic disorders and statin use: a propensity score-matched analysis. Pharmacotherapy 2013, 33:615-626.
37. Otte C., Zhao S., Whooley M.A. Statin use and risk of depression in patients with coronary heart disease; longitudinal data from the Heart and Soul Study. JClin Psychiatry 2012, 73:610-615.
38. McKinney J.S., Kostis W.J. Statin therapy and the risk of intracerebral haemorrhage: a meta-analysis of 31 randomized controlled trials. Stroke 2012, 43:2149-2156.
39. Amarenco P., Bogousslavsky J., Callahan A., et al. High-dose atorvastatin after stroke or transient ischemic attack. NEngl J Med 2006, 355:549-559.
40. Baigent C., Blackwell L., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681. Cholesterol Treatment Trialists' (CTT) Collaboration.
41. Haussen D.C., Henninger N., Kumar S., Selim M. Statin use and microbleeds in patients with spontaneous intracerebral haemorrhage. Stroke 2012, 43:2677-2681.
42. Hermans M.P., Ahn S.A., Rousseau M.F. Statin therapy and cataract in type 2 diabetes. Diabetes Metab 2011, 37:139-143.
43. Machan C.M., Hrynchak P.K., Irving E.L. Age-related cataract is associated with type 2 diabetes and statin use. Optom Vis Sci 2012, 89:1165-1171.
44. Fong D.S., Poon K.Y. Recent statin use and cataract surgery. Am J Ophthalmol 2012, 153. 222-8.e1.
45. Leuschen J., Mortensen E.M., Frei C.R., Mansi E.A., Panday V., Mansi I. Association of statin use with cataracts: a propensity score-matched analysis. JAMA Ophthalmol 2013, [Epub ahead of print].
46. Buettner C., Rippberger M.J., Smith J.K., Leveille S.G., Davis R.B., Mittleman M.A. Statin use and musculoskeletal pain among adults with and without arthritis. Am J Med 2012, 125:176-182.
47. de Jong H.J., Klungel O.H., van Dijk L., et al. Use of statins is associated with an increased risk of rheumatoid arthritis. Ann Rheum Dis 2012, 71:648-654.
48. Kumar P., Kennedy G., Khan F., Pullar T., Belch J.J. Rosuvastatin might have an effect on C-reactive protein but not on rheumatoid disease activity: Tayside randomized controlled study. Scott Med J 2012, 57:80-83.
49. Myasoedova E., Gabriel S.E., Green A.B., Matteson E.L., Crowson C.S. The impact of statin use on lipid levels in statin-naive patients with rheumatoid arthritis (RA) vs. non-RA subjects: results from a population-based study. Arthritis Care Res (Hoboken) 2013, 65:1592-1599.
50. De Vera M.A., Choi H., Abrahamowicz M., Kopec J., Lacaille D. Impact of statin discontinuation on mortality in patients with rheumatoid arthritis: a population-based study. Arthritis Care Res (Hoboken) 2012, 64:809-816.
51. Schanberg L.E., Sandborg C., Barnhart H.X., et al. Use of atorvastatin in systemic lupus erythematosus in children and adolescents. Arthritis Rheum 2012, 64:285-296.
52. de Jong H.J., Tervaert J.W., Saldi S.R., et al. Association between statin use and lupus-like syndrome using spontaneous reports. Semin Arthritis Rheum 2011, 41:373-381.
53. de Jong H.J., Saldi S.R., Klungel O.H., et al. Statin-associated polymyalgia rheumatica. An analysis using WHO global individual case safety database: a case/non-case approach. PLoS One 2012, 7:e41289.
54. Moulis G., Béné J., Sommet A., et al. Statin-induced lupus: a case/non-case study in a nationwide pharmacovigilance database. Lupus 2012, 21:885-889.
55. Massay R.J., Maynard A.A. Pityriasis lichenoides chronica associated with use of HMG-CoA reductase inhibitors. West Indian Med J 2012, 61:743-745.
56. Kwon H., Lee S.H., Kim S.E., et al. Spontaneously reported hepatic adverse drug events in Korea: multicenter study. JKorean Med Sci 2012, 27:268-273.
57. Björnsson E., Jacobsen E.I., Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. JHepatol 2012, 56:374-380.
58. Bergmann O.M., Kristjansson G., Jonasson J.G., Björnsson E.S. Jaundice due to suspected statin hepatotoxicity: a case series. Dig Dis Sci 2012, 57:1959-1964.
59. Malaguarnera M., Vacante M., Russo C., et al. Rosuvastatin reduces nonalcoholic fatty liver disease in patients with chronic hepatitis C treated with α-interferon and ribavirin: rosuvastatin reduces NAFLD in HCV patients. Hepat Mon 2011, 11:92-98.
60. Han K.H., Rha S.W., Kang H.J., et al. Evaluation of short-term safety and efficacy of HMG-CoA reductase inhibitors in hypercholesterolemic patients with elevated serum alanine transaminase concentrations: PITCH study (PITavastatin versus atorvastatin to evaluate the effect on patients with hypercholesterolemia and mild to moderate hepatic damage). JClin Lipidol 2012, 6:340-351.
61. Abdulrazzaq H.A., Sulaiman S.A. Why cardiac patients discontinued lipid lowering agents: views on gastrointestinal adverse reactions and their risk factors. Int J Pharm Pharm Sci 2012, 4(suppl 1):374-378.
62. Stein E.A., Vidt D.G., Shepherd J., Cain V.A., Anzalone D., Cressman M.D. Renal safety of intensive cholesterol-lowering treatment with rosuvastatin: a retrospective analysis of renal adverse events among 40,600 participants in the rosuvastatin clinical development program. Atherosclerosis 2012, 221:471-477.
63. Upadhyay A., Earley A., Lamont J.L., Haynes S., Wanner C., Balk E.M. Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012, 157:251-262.
64. Palmer S.C., Craig J.C., Navaneethan S.D., Tonelli M., Pellegrini F., Strippoli G.F. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012, 157:263-275.
65. Morgan R.E., Campbell S.E., Yu C.Y., Sponseller C.A., Muster H.A. Comparison of the safety, tolerability, and pharmacokinetic profile of a single oral dose of pitavastatin 4 mg in adult subjects with severe renal impairment not on hemodialysis versus healthy adult subjects. JCardiovasc Pharmacol 2012, 60:42-48.
66. Dormuth C.R., Hemmelgarn B.R., Paterson J.M., et al. Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases. BMJ 2013, 346:f880.
67. Robles N.R., Velasco J., Mena C., Polo J., Angulo E., Espinosa J. Increased frequency of microalbuminuria in patients receiving statins. Clin Lipidol 2013, 8:257-262.
68. van der Tol A., Van Biesen W., Van Laecke S., et al. Statin use and the presence of microalbuminuria. Results from the ERICABEL trial: a non-interventional epidemiological cohort study. PLoS One 2012, 7:e31639.
69. Sattar N., Preiss D., Murray H.M., et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010, 375:735-742.
70. Colbert J.D., Stone J.A. Statin use and the risk of incident diabetes mellitus: a review of the literature. Can J Cardiol 2012, 28:581-589.
71. Thongtang N., Ai M., Otokozawa S., et al. Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation. Am J Cardiol 2011, 107:387-392.
72. Moutzouri E., Liberopoulos E., Mikhailidis D.P., et al. Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance. Int J Clin Pract 2011, 65:1141-1148.
73. Martin S., Herder C., Schloot N.C., et al. Residual beta cell function in newly diagnosed type 1 diabetes after treatment with atorvastatin: the randomized DIATOR Trial. PLoS One 2011, 6:e17554.
74. Preiss D., Seshasai S.R., Welsh P., et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011, 305:2556-2564.
75. Ridker P.M., Pradhan A., MacFadyen J.G., Libby P., Glynn R.J. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012, 380:565-571.
76. Carter A.A., Gomes T., Camacho X., Juurlink D.N., Shah B.R., Mamdani M.M. Risk of incident diabetes among patients treated with statins: population based study. BMJ 2013, 346:f2610.
77. Ma T., Tien L., Fang C.L., Liou Y.S., Jong G.P. Statins and new-onset diabetes: a retrospective longitudinal cohort study. Clin Ther 2012, 34:1977-1983.
78. Wang K.L., Liu C.J., Chao T.F., et al. Statins, risk of diabetes, and implications on outcomes in the general population. JAm Coll Cardiol 2012, 60:1231-1238.
79. Culver A.L., Ockene I.S., Balasubramanian R., et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med 2012, 172:144-152.
80. Tatonetti N.P., Denny J.C., Murphy S.N., et al. Detecting drug interactions from adverse-event reports: interaction between paroxetine and pravastatin increases blood glucose levels. Clin Pharmacol Ther 2011, 90:133-142.
81. Burghardt K.J., Pop-Busui R., Bly M.J., Grove T.B., Taylor S.F., Ellingrod V.L. The influence of the brain-derived neurotropic factor Val66Met genotype and HMG-CoA reductase inhibitors on insulin resistance in the schizophrenia and bipolar populations. Clin Transl Sci 2012, 5:486-490.
82. Ko D.T., Wijeysundera H.C., Jackevicius C.A., Yousef A., Wang J., Tu J.V. Diabetes mellitus and cardiovascular events in older patients with myocardial infarction prescribed intensive-dose and moderate-dose statins. Circ Cardiovasc Qual Outcomes 2013, 6:315-322.
83. Waters D.D., Ho J.E., DeMicco D.A., et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. JAm Coll Cardiol 2011, 57:1535-1545.
84. Deedwania P., Barter P., Carmena R., et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 2006, 368:919-928.
85. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364:685-696.
86. Kearney P.M., Blackwell L., et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008, 371:117-125. Cholesterol Treatment Trialists' (CTT) Collaborators.
87. Gokce M&Idot, Gülpinar Ö., Öztürk E., Güleç S., Yaman Ö. Effect of atorvastatin on erectile functions in comparison with regular tadalafil use. A prospective single-blind study. Int Urol Nephrol 2012, 44:683-687.
88. Roberto G., Biagi C., Montanaro N., Koci A., Moretti U., Motola D. Statin-associated gynecomastia: evidence coming from the Italian spontaneous ADR reporting database and literature. Eur J Clin Pharmacol 2012, 68:1007-1011.
89. Xu J.-F., Washko G.R., Nakahira K., et al. Statins and pulmonary fibrosis: the potential role of NLRP3 inflammasome activation. Am J Respir Crit Care Med 2012, 185:547-556.
90. Vinogradova Y., Coupland C., Hippisley-Cox J. Risk of pneumonia in patients taking statins: population-based nested case-control study. Br J Gen Pract 2011, 61:e742-e748.
91. Mancini G.B., Etminan M., Zhang B., Levesque L.E., FitzGerald J.M., Brophy J.M. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. JAm Coll Cardiol 2006, 47:2554-2560.
92. Marelli C., Gunnarsson C., Ross S., et al. Statins and risk of cancer: a retrospective cohort analysis of 45,857 matched pairs from an electronic medical records database of 11 million adult Americans. JAm Coll Cardiol 2011, 58:530-537.
93. Lee J.E., Baba Y., Ng K., et al. Statin use and colorectal cancer risk according to molecular subtypes in two large prospective cohort studies. Cancer Prev Res (Phila) 2011, 4:1808-1815.
94. Kuo C.C., Chiu H.F., Lee I.M., Kuo H.W., Lee C.T., Yang C.Y. Statin use and the risk of bladder cancer: a population-based case-control study. Expert Opin Drug Saf 2012, 11:733-738.
95. Jacobs E.J., Newton C.C., Thun M., Gapstur S.M. Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer Res 2011, 71:1763-1771.
96. Fröhlich G.M., Rufibach K., Enseleit F., et al. Statins and the risk of cancer after heart transplantation. Circulation 2012, 126:440-447.
97. Gaist D., Andersen L., Hallas J., Toft Sørensen H., Schrøder H.D., Friis S. Use of statins and risk of glioma: a nationwide case-control study in Denmark. Br J Cancer 2013, 108:715-720.
98. Tsan Y.T., Lee C.H., Ho W.C., Lin M.H., Wang J.D., Chen P.C. Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection. JClin Oncol 2013, 31:1514-1521.
99. Higgins M.J., Prowell T.M., Blackford A.L. Ashort-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer. Breast Cancer Res Treat 2012, 131:915-924.
100. Kontraros M., Varkarakis I., Ntoumas K., Deliveliotis C. Pathological characteristics, biochemical recurrence and functional outcome in radical prostatectomy patients on statin therapy. Urol Int 2013, 90:263-269.
101. Feng Q., Wilke R.A., Baye T.M. Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions. Pharmacogenomics 2012, 13:579-594.
102. Link E., Parish S., et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. NEngl J Med 2008, 359:789-799. SEARCH Collaborative Group.
103. Francesca Notarangelo M., Marziliano N., Antonietta Demola M., et al. Genetic predisposition to atorvastatin-induced myopathy: a case report. JClin Pharm Ther 2012, 37:604-606.
104. Brunham L.R., Lansberg P.J., Zhang L., et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J 2012, 12:233-237.
105. Donnelly L.A., Doney A.S.F., Tavendale R., et al. Common nonsynonymous substitutions in SCLO1B1 predispose to statin intolerance in routinely treated indivudals with type 2 diabetes: a Go-DARTS study. Clin Pharmacol Ther 2011, 89:210-216.
106. Hu M., Mak V.W., Tomlinson B. Intronic variants in SLCO1B1 related to statin-induced myopathy are associated with the low-density lipoprotein cholesterol response to statins in Chinese patients with hyperlipidaemia. Pharmacogenet Genomics 2012, 22:803-806.
107. Isackson P.J., Ochs-Balcom H.M., Ma C., et al. Association of common variants in the human eyes shut ortholog (EYS) with statin-induced myopathy: evidence for additional functions of EYS. Muscle Nerve 2011, 44:531-538.
108. Hoenig M.R., Walker P.J., Gurnsey C., Beadle K., Johnson L. The C3435T polymorphism in ABCB1 influences atorvastatin efficacy and muscle symptoms in a high-risk vascular cohort. JClin Lipidol 2011, 5:91-96.
109. Vladutiu G.D., Isackson P.J., Kaufman K., et al. Genetic risk for malignant hyperthermia in non-anesthesia-induced myopathies. Mol Genet Metab 2011, 104:167-173.
110. Mangravite L.M., Engelhardt B.E., Medina M.W., et al. Astatin-dependent QTL for GATM expression is associated with statin-induced myopathy. Nature 2013, 502:377-380.
111. Degorter M.K., Tirona R.G., Schwarz U.I., et al. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. Circ Cardiovasc Genet 2013, 6:400-408.
112. Holbrook A., Wright M., Sung M., Ribic C., Baker S. Statin-associated rhabdomyolysis: is there a dose-response relationship?. Can J Cardiol 2011, 27:146-151.
113. Oshima Y. Characteristics of drug-associated rhabdomyolysis: analysis of 8,610 cases reported to the U.S. Food and Drug Administration. Intern Med 2011, 50:845-853.
114. El-Salem K., Ababneh B., Rudnicki S., et al. Prevalence and risk factors of muscle complications secondary to statins. Muscle Nerve 2011, 44:877-881.
115. Shahan J.L., Panu L.D., Hildebrandt G.C. Rhabdomyolysis in a multiple myeloma patient secondary to concurrent treatment with lenalidomide and pravastatin and to lenalidomide alone. Int J Hematol 2012, 96:818-819.
116. Marusic S., Lisicic A., Horvatic I., Bacic-Vrca V., Bozina N. Atorvastatin-related rhabdomyolysis and acute renal failure in a genetically predisposed patient with potential drug-drug interaction. Int J Clin Pharm 2012, 34:825-827.
117. Mackay J.W., Fenech M.E., Myint K.S. Acute rhabdomyolysis caused by concurrent therapy with atorvastatin and warfarin. Br J Hosp Med (Lond) 2012, 73:106-107.
118. Noordally S.O., Sohawon S., Vanderhulst J., Duttmann R., Corazza F., Devriendt J. Afatal case of cutaneous adverse drug-induced toxic epidermal necrolysis associated with severe rhabdomyolysis. Ann Saudi Med 2012, 32:309-311.
119. Goldenberg G., Khan R., Bharathan T. Interaction between simvastatin and cranberry juice in an elder. Clin Geriatr 2012, 20:38-42.
120. Fallah A., Deep M., Smallwood D., Hughes P. Life-threatening rhabdomyolysis following the interaction of two commonly prescribed medications. Australas Med J 2013, 6:112-114.
121. Bhome R., Penn H. Rhabdomyolysis precipitated by a sitagliptin-atorvastatin drug interaction. Diabet Med 2012, 29:693-694.
122. Alreja G., Inayatullah S., Goel S., Braden G. Rhabdomyolysis caused by an unusual interaction between azithromycin and simvastatin. JCardiovasc Dis Res 2012, 3:319-322.
123. Doran E., Iedema J., Ryan L., Coombes I. Fatal rhabdomyolysis following voriconazole and simvastatin. Aust Prescr 2012, 35:88-89.
124. Elazzazy S., Eziada S.S., Zaidan M. Rhabdomyolysis secondary to drug interaction between atorvastatin, omeprazole, and dexamethasone. Int Med Case Rep J 2012, 5:59-61.
125. Oh D.H., Chan S.Q., Wilson A.M. Myopathy and possible intestinal dysfunction in a patient treated with colchicine and simvastatin. Med J Aust 2012, 197:332-333.
126. Kearney S., Carr A.S., McConville J., McCarron M.O. Northern Ireland Neurology Network. Rhabdomyolysis after co-prescription of statin and fusidic acid. BMJ 2012, 345:e6562.
127. Gabignon C., Zeller V., Le Guyader N., Desplaces N., Lidove O., Ziza J.M. Rhabdomyolysis following the coprescription of atorvastatin and fusidic acid. Rev Med Interne 2013, 34:39-41.
128. Patel A.M., Shariff S., Bailey D.G., et al. Statin toxicity from macrolide antibiotic coprescription: a population-based cohort study. Ann Intern Med 2013, 158:869-876.
129. Egan A., Colman E. Weighing the benefits of high-dose simvastatin against the risk of myopathy. New Engl J Med 2011, 365:285-287.
130. Rowan C.G., Brunelli S.M., Munson J., et al. Clinical importance of the drug interaction between statins and CYP3A4 inhibitors: a retrospective cohort study in The Health Improvement Network. Pharmacoepidemiol Drug Saf 2012, 21:494-506.
131. Yu C.Y., Campbell S.E., Zhu B., et al. Effect of pitavastatin vs. rosuvastatin on international normalized ratio in healthy volunteers on steady-state warfarin. Curr Med Res Opin 2012, 28:187-194.
132. Harris L.J., Thapa R., Brown M., et al. Clinical and laboratory phenotype of patients experiencing statin intolerance attributable to myalgia. JClin Lipidol 2011, 5:299-307.
133. Elhayany A., Mishaal R.A., Vinker S. Is there clinical benefit to routine enzyme testing of patients on statins?. Expert Opin Drug Saf 2012, 11:185-190.
134. Skottheim I.B., Bogsrud M.P., Hermann M., Retterstol K., Asberg A. Atorvastatin metabolite measurements as a diagnostic tool for statin-induced myopathy. Mol Diagn Ther 2011, 15:221-227.
135. Sidhu H.S., Venkatanarasimha N., Bhatnagar G., Vardhanabhuti V., Fox B.M., Suresh S.P. Imaging features of therapeutic drug-induced musculoskeletal abnormalities. Radiographics 2012, 32:105-127.
136. Collins G.S., Altman D.G. Predicting the adverse risk of statin treatment: an independent and external validation of Qstatin risk scores in the UK. Heart 2012, 98:1091-1097.
137. Cohen J.D., Brinton E.A., Ito M.K., Jacobson T.A. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. JClin Lipidol 2012, 6:208-215.
138. Fung E.C., Crook M.A. Statin myopathy: a lipid clinic experience on the tolerability of statin rechallenge. Cardiovasc Ther 2012, 30:e212-e218.
139. Zhang H., Plutzky J., Skentzos S., et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med 2013, 158:526-534.
140. Mampuya W.M., Frid D., Rocco M., et al. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. Am Heart J 2013, 166:597-603.
141. Goldberg A.S., Degorter M.K., Ban M.R., Kim R.B., Hegele R.A. Efficacy and plasma drug concentrations with nondaily dosing of rosuvastatin. Can J Cardiol 2013, 29:915-919.
142. Kennedy S.P., Barnas G.P., Schmidt M.J., Glisczinski M.S., Paniagua A.C. Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance. JClin Lipidol 2011, 5:308-315.
143. Meek C., Wierzbicki A.S., Jewkes C., et al. Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients: an observational study. Curr Med Res Opin 2012, 28:371-378.
144. Glueck C.J., Budhani S.B., Masineni S.S., et al. Vitamin D deficiency, myositis-myalgia, and reversible statin intolerance. Curr Med Res Opin 2011, 27:1683-1690.
145. Kurnik D., Hochman I., Vesterman-Landes J., et al. Muscle pain and serum creatine kinase are not associated with low serum 25(OH) vitamin D levels in patients receiving statins. Clin Endocrinol (Oxf) 2012, 77:36-41.
146. Riphagen I.J., van der Veer E., Muskiet F.A., DeJongste M.J. Myopathy during statin therapy in the daily practice of an outpatient cardiology clinic: prevalence, predictors and relation with vitamin D. Curr Med Res Opin 2012, 28:1247-1252.
147. Zlatohlavek L., Vrablik M., Grauova B., Motykova E., Ceska R. The effect of coenzyme Q10 in statin myopathy. Neuro Endocrinol Lett 2012, 33(suppl 2):98-101.
148. Fedacko J., Pella D., Fedackova P., et al. Coenzyme Q(10) and selenium in statin-associated myopathy treatment. Can J Physiol Pharmacol 2013, 91:165-170.
149. Bookstaver D.A., Burkhalter N.A., Hatzigeorgiou C. Effect of coenzyme Q10 supplementation on statin-induced myalgias. Am J Cardiol 2012, 110:526-529.
150. Karl M., Rubenstein M., Rudnick C., Brejda J. Amulticenter study of nutraceutical drinks for cholesterol (evaluating effectiveness and tolerability). JClin Lipidol 2012, 6:150-158.
151. Visser M.E., Wagener G., Baker B.F., et al. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol inhigh-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J 2012, 33:1142-1149.
152. Sullivan D., Olsson A.G., Scott R., et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 2012, 308:2497-2506.
153. Cuchel M., Meagher E.A., du Toit Theron H., et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 2013, 381:40-46.
154. Naci H., Brugts J., Ades T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials. Circ Cardiovasc Qual Outcomes 2013, 6:390-399.
155. Anderson T.J., Gregoire J., Hegele R.A., et al. 2012 Update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 2013, 29:151-167.